The authors reply

New England Journal of Medicine

Volumn 373, Issue 15, 2015, Pages 1476-1477

  Cannon, Christopher P ^a   Blazing, Michael A ^b   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DNA POLYMORPHISM; DRUG EFFICACY; HUMAN; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; LETTER; MONOTHERAPY; NPC1L1 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; FEMALE; MALE;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; SIMVASTATIN;

EID: 84943365028     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1509363     Document Type: Letter

References (5)

1. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012;223:251-61.
2. Lakoski SG, Xu F, Vega GL, et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 2010;95:800-9.
3. Blazing M. On-treatment analysis of IMPROVE IT. Presented at the American Heart Association Scientific Sessions, Chicago, November 15-19, 2014 (http://www.timi.org/uploads/pdfs/ improve-it-on-treatment-aha-120414.pptx).
4. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: A 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015;65:1552-61.
5. The Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371:2072-82.